Nuage Therapeutics

Nuage Therapeutics is a biopharmaceutical company based in Barcelona, Spain, focused on drug discovery for intrinsically disordered proteins (IDPs). Founded in 2021 as a spin-off from IRB Barcelona and ICREA, the company aims to develop precision therapies for aggressive cancers that have limited treatment options. Its leadership team includes experienced professionals from both academic and industrial backgrounds.

The company has created proprietary drug screening assays that target IDPs undergoing biomolecular condensation. This innovative technology allows Nuage to explore the transient states of these proteins, addressing challenges in drug discovery. Currently, Nuage is working on developing new drugs for castration-resistant prostate cancer and has received funding to advance treatments for aggressive lung cancer. The company has secured investment from notable partners, including Sofinnova Partners and the Asociación Española contra el Cáncer.